To the Editor:
Low-dose vemurafenib in hairy cell leukemia patients with active infection
To the Editor:
Classic hairy cell leukemia (HCL) is a rare indolent B-cell malignancy. 1 Standard treatment with purine analogues is highly effective, but also associated with profound myelotoxicity. 2, 3 As such, patients with ongoing infection do not qualify for purine analogues and still represent a therapeutic challenge. Recently, the BRAF-inhibitor vemurafenib was suggested an adequate treatment alternative, 4 but feasibility data remain scarce.
We here report our long-term experience of six HCL patients with active infection, who achieved durable hematological remissions with low-dose vemurafenib.
Case 1: A 68-year-old woman was diagnosed with HCL 14 years ago. Frontline treatment with cladribine achieved a complete remission (CR) of 104 months. With 84% hairy cell (HC) infiltration in the bone marrow (BM) at relapse re-/treatment with cladribine and rituximab did not yield any response, but resulted in severe infectious complications (Table S1 ). In the absence of other approved therapeutic alternatives, vemurafenib (480 mg/day) was applied off-label with confirmed BRAF V600E mutation. Within 2 weeks rapid recovery of peripheral blood (PB) counts ( Figure 1 ) and adequate infection control was achieved. Treatment was well tolerated without any adverse events (AE). Due to excellent response and risk of secondary skin cancers, vemurafenib was discontinued after 3 months and BM biopsy confirmed CR (ongoing for 76 months). Vemurafenib was discontinued at month 3 in PR (BM biopsy: <40% HC infiltration) owing to concerns about secondary skin cancers. At relapse 10 months later vemurafenib (480 mg/day) re-exposure was chosen due to pneumonia. PR was achieved after 3 months now allowing cladribine consolidation therapy (Table S1 ). (Table S1 ). At relapse complicated by recurrent urinary tract infections vemurafenib (480 mg/day) was given as offlabel treatment with confirmed BRAF V600E mutation. Within a few weeks HC were cleared from PB ( Figure 1 ). Given PR as deepest response 3 months on treatment (0.5% HC in PB) and excellent tolerability, vemurafenib has been applied continuously for 32 months so far.
Serial dermatologic follow-up included, no AE have been noted. On day 14 vemurafenib was prematurely discontinued based on transient liver enzyme elevation. Nevertheless, the patient remains in PR with a follow-up of 10 months.
Given an overall response rate of nearly 100% without additional myelotoxicity in 60 relapsed/refractory HCL patients, the BRAFinhibitor vemurafenib (1920 mg/day) promised to offer an ideal salvage treatment for those with active infection. 4, 5 Study enrollment criteria, however, excluded this patient subpopulation and the feasibility of vemurafenib in this setting remains to be better defined.
Moreover, optimal vemurafenib dosing and scheduling in HCL is still unclear as AE required dose reduction in >50% of study patients 4 and lower doses (480-960 mg/day) seem similarly effective. 6 Finally, other than in melanoma in HCL trials treatment-time was limited to a few months due to concerns about drug-related skin tumors, partially contributing to a median PFS of only approximately 9 months. 4 In these patients our long-term follow-up illustrates feasibility and efficacy of continuous vemurafenib dosing until disease progression as done in melanoma. In patients not relapsed/refractory to purine analogues +/− rituximab our data suggest that rapid infection control with a short course of vemurafenib may provide if necessary a window of opportunity to subsequent consolidation therapy. 
